EUVIMEDAtklāt EUVIMED
Open access · CC BY 4.0

Research Progress and Clinical Translation Prospects of Polysaccharide-Based Drugs in Anti-Hepatocellular Carcinoma Therapy

Jiaxin Tang, Huiying Teng, Xiaona Li, Yanping Xu, Hongxuan Li, Zheyi Xu, Xin Liu

Frontiers in Healthcare Technology · 2026

DOI: 10.71465/fht753 ↗

At a glance

Journal article in Frontiers in Healthcare Technology, 2026. Written by Jiaxin Tang and 6 co-authors. The full text is freely available (open access, CC BY 4.0).

AbstraktsBibliogrāfiskie datiCiteRelated studies

Abstract (original language)

Hepatocellular carcinoma (HCC), a highly lethal malignancy worldwide, faces significant clinical treatment challenges due to tumor heterogeneity, multidrug resistance, and therapeutic limitations. There is an urgent need for the development of novel, highly effective, and low-toxicity therapeutic agents [1]. Polysaccharides, natural macromolecular compounds widely found in plants, fungi, and marine organisms, possess advantages such as good biocompatibility, multi-target characteristics, and low toxicity, making them a significant focus in anti-HCC drug development [2]. This article systematically reviews the anti-HCC mechanisms of polysaccharide-based drugs, including direct inhibition of tumor cell proliferation, induction of apoptosis, cell cycle arrest, suppression of invasion and metastasis, as well as indirect pathways such as regulating the tumor immune microenvironment and reversing chemotherapy resistance. It elaborates on the anti-HCC activity and structural characteristics of representative polysaccharides from sources like Astragalus, Bupleurum, and Phyllanthus emblica, analyzing the regulatory role of structure-activity relationships on their bioactivity. Furthermore, it summarizes the research progress in applying polysaccharides in nano-targeted delivery systems for HCC. Key challenges hindering the clinical translation of polysaccharide-based drugs, including low bioavailability, insufficiently elucidated mechanisms, and lack of unified quality control standards, are analyzed. Finally, future research directions and clinical application prospects are discussed, aiming to provide a theoretical reference and practical basis for fundamental research and industrial development of polysaccharide-based anti-HCC drugs.

Cite

APA

Tang, J., Teng, H., Li, X., Xu, Y., Li, H., Xu, Z., & Liu, X. (2026). Research Progress and Clinical Translation Prospects of Polysaccharide-Based Drugs in Anti-Hepatocellular Carcinoma Therapy. Frontiers in Healthcare Technology. https://doi.org/10.71465/fht753

Vancouver

Tang J, Teng H, Li X, Xu Y, Li H, Xu Z, et al. Research Progress and Clinical Translation Prospects of Polysaccharide-Based Drugs in Anti-Hepatocellular Carcinoma Therapy. Frontiers in Healthcare Technology. 2026. doi:10.71465/fht753

BibTeX
@article{Tang2026,
  author = {Tang, Jiaxin and Teng, Huiying and Li, Xiaona and Xu, Yanping and Li, Hongxuan and Xu, Zheyi and Liu, Xin},
  title = {Research Progress and Clinical Translation Prospects of Polysaccharide-Based Drugs in Anti-Hepatocellular Carcinoma Therapy},
  journal = {Frontiers in Healthcare Technology},
  year = {2026},
  doi = {10.71465/fht753}
}
Start for free →